Patrick Hecht

Appearances

EFFICACY AND SAFETY OF UPADACITINIB FOR THE TREATMENT OF FISTULAS AND FISSURES IN PATIENTS WITH CROHN’S DISEASE
Date
May 9, 2023
BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…
Presenter
Jean Frederic Colombel
Icahn School of Medicine at Mount Sinai
Speakers
Peter Irving
Florian Rieder
Cleveland Clinic Foundation
Remo Panaccione
David Schwartz
Ryohei Hayashi
Xuan Zhu
Ana Lacerda
Elena Dubcenco
Elena Marced
Patrick Hecht
Tian Feng
Sofie Berg
Walter Reinisch
ADDITIONAL RISANKIZUMAB THERAPY IS EFFECTIVE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO DID NOT ACHIEVE CLINICAL RESPONSE TO INITIAL 12-WEEK INDUCTION THERAPY: AN ANALYSIS OF PHASE 3 INSPIRE AND COMMAND STUDIES
Date
May 20, 2024
BACKGROUND: Risankizumab (RZB), an anti-interleukin 23p19 monoclonal antibody, demonstrated efficacy for moderately to severely active ulcerative colitis (UC) in the 12-week phase 3 INSPIRE induction study (NCT03398148)…
Presenter
Remo Panaccione
Speakers
Gil Melmed
David Drobne
Manreet Kaur
Silvio Danese
Tadakazu Hisamatsu
Phillip Levine
Ezequiel Neimark
Su Chen
Ling Cheng
W Rachel Duan
Ramona Vladea
Patrick Hecht
Edouard Louis